RxDoctor Payments Data

Slayton Ebeling

Optometrist · Dallas, TXNPI 1629459862

Payments from drug & device makers

$12,990in general payments, 2019–2025

Across 194 payments — averaging $66.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyevance Pharmaceuticals LLC$8K
  • AbbVie$1K
  • Alcon$716
  • Sun Pharmaceutical Industries Inc.$339
  • Tarsus Pharmaceuticals, Inc.$322
  • Aerie Pharmaceuticals, Inc.$282
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,0008%
  • Speaking & faculty fees$5,65043%
  • Travel & lodging$5444%
  • Food & beverage$5,48542%
  • Education$761%
  • Gifts$2352%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,990 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$176,105
Medicare patients
980
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$31,528
XiidraLifitegrast31$20,539
LumiganBimatoprost18$10,154
Tobramycin-DexamethasoneTobramycin/Dexamethasone173$7,035
Prednisolone Acetate156$4,876
Cyclosporine13$3,719
Latanoprost386$3,104
Travoprost18$2,726
Alphagan PBrimonidine Tartrate11$2,238
Brimonidine Tartrate36$2,231
Fluorometholone17$1,227
Timolol Maleate59$905
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat61$850
Carteolol Hcl17$462
Dorzolamide Hcl19$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$1,057$43,91975 claims
Bausch & Lomb Americas Inc.Xiidra$225$20,53931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →